^
Association details:
| Biomarker: | CXCL12 overexpression |
|---|---|
| Cancer: | T Cell Non-Hodgkin Lymphoma |
| Drug: | Zarnestra (tipifarnib) (CXCL12 inhibitor, Farnesyl transferase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Proof of Concept for Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+ Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study
Published date:
11/06/2019
Excerpt:
50 PTCL pts (23 AITL, 25 PTCL-NOS, 1 ALK- ALCL, 1 gamma-delta TCL) have been treated with tipifarnib,...AITL tumors expressed high levels of CXCL12 and responded to tipifarnib,…
DOI:
https://doi.org/10.1182/blood-2019-128513
Trial ID:
